Interview: Real World Evidence’s Commercial Facet
Executive Summary
Senior QuintilesIMS officials tell Scrip that harnessing real world evidence (RWE) insights on the commercial side is not quite the “norm” yet across pharmaceutical companies, although it can provide up to $1bn in value across lifecycle. They also explain the growing significance of RWE in the Middle East.